FDA Approved: PRALUENT — Original Application (Regeneron Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved the original application for PRALUENT (alirocumab) by Regeneron. It is indicated to lower LDL cholesterol in adults with heterozygous familial hype…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease
• Heterozygous Familial Hypercholesterolemia

Drugs mentioned

• Praluent (alirocumab)

Snippet

ORIG AP for PRALUENT (ALIROCUMAB)